Introduction {#Sec1}
============

Gas bubbles in the micrometer range are ideal contrast agents for ultrasound imaging because of their high compressibility and low density, giving excellent reflectance of ultrasound waves (acoustic backscatter) \[[@CR1]\]. Ultrasound contrast signals from free gas bubbles in vivo in the human heart were first observed in 1968 after direct intracardiac injection \[[@CR2]\]. Short bubble lifetime urged development of more stable agents giving more persistent contrast on the arterial side after intravenous injection and passage through the lung capillaries. The ultimate goal is to generate contrast in the heart muscle (myocardium). Suspensions of solid particles, emulsified liquid droplets, free and encapsulated gases or liquids \[[@CR3]\] have been proposed as ultrasound contrast agents (USCA). Efficient USCA may comprise micron-sized bubbles stabilized by a thin, potentially biodegradable flexible membrane consisting of polymers \[[@CR4]\] or phospholipids \[[@CR5]\]. However, carbohydrate-based gas-releasing systems, generating free gas bubbles after intravenous injection of a particle suspension, eliminate the challenge of developing a stabilized bubble suspension as a drug product, with demands of long term shelf stability. In the commercially available agent SHU 454 (Echovist®, Schering AG, Berlin), milled, particulate water-soluble α-[d]{.smallcaps}-galactose acts as a precursor for gas bubbles, and is in clinical use in enhanced hystero-sonography \[[@CR6]\]. The gas-releasing powder is prepared using ball-milling of commercial α-[d]{.smallcaps}-galactose, giving clusters of particles with a mean size of about 40 μm, with air-filled voids between them \[[@CR7]\]. Upon dissolution in water, the clusters release the air trapped in the clusters and gas bubbles are generated. The α-[d]{.smallcaps}-galactose crystals dissolve in the water phase while acting as short-living nucleation sites for the gas bubbles \[[@CR7]\]. Lack of myocardial contrast enhancement (MCE) with SHU 454 in humans led to the improved agent SHU 508 (Levovist®, Schering AG, Berlin), wherein α-[d]{.smallcaps}-galactose is milled with 0.1% palmitic acid \[[@CR8]\]. However, in spite of more persisting contrast on the arterial side of the heart with SHU 508 \[[@CR9]\], it is not in clinical use to study early reduced blood flow in the myocardium using MCE. Since preformed, lyophilized phospholipid-stabilized gas bubbles on the market have been a success \[[@CR10]\], the simplicity of the gas-releasing carbohydrate-based products in the form of a dry, particulate, water-soluble precursor of gas bubbles encouraging further research. In the present research, our first aim was to investigate if lifetime of the populations of gas bubbles released could be prolonged, by investigating a broad range of amphiphilic compounds. Our second aim was to investigate if acoustic attenuation vs. time (390 s) area under the curve could be used as a suitable screening tool in this research.

Experimental Section {#Sec2}
====================

Materials {#Sec3}
---------

### Chemicals {#Sec4}

Starch was purchased from Reppal PSM 70, Reppe Glykos (Sweden). α-[d]{.smallcaps}-Xylose was purchased from BDH (Basel, Switzerland). 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine (DPPC) and 1,2-dioleoyl-*sn*-glycero-3-phosphatidylethanolamine (DOPE) were purchased from Avanti Polar Lipids, USA. Human serum albumin (HSA), sodium dodecyl sulfate (Sodium lauryl sulfate, Na-LS), 2-sulfobutanedioic acid 1,4-*bis*(2-ethylhexyl) ester sodium salt (Na-docusate), Pluronic^®^ F68 ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \overline{Mw} $$\end{document}$ 8.4 kDa) a very hydrophilic polyoxyethylene polyoxypropylene triblock copolymer (abbreviated HTBCP), sorbitan mono-oleate isomer mixture (Span 80) abbreviated SMO, sorbitan tri-oleate isomer mixture Span 85) abbreviated STO, α-linolenic acid ((*Z*,*Z*,*Z*)-9,12,15-octadecatrienoic acid) and other fatty acids were purchased from Sigma Chemical Company (St. Louis, MO). Tricosa-10,12-diynoic acid was purchased from ABCR GmbH & Co. (Karlsruhe, Germany). Hexadecanedioic acid, α-cyclodextrin, dextran ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \overline{Mw} $$\end{document}$ 20 kD), maltodextrin, glycogen, α-[d]{.smallcaps}-galactose and all other chemicals were purchased from Fluka Chemie AG (Buchs, Switzerland) or E. Merck AG (Darmstadt, Germany). Scheme [1](#Sch1){ref-type="fig"} gives the structures of the used compounds except for the oligo and polysaccharides. Deionized water was used throughout the experiments. Chemical structures and names of the compounds used in the present work are given in Scheme [1](#Sch1){ref-type="fig"}.Scheme 1Chemical structures and names of the compounds used. The structures of starch, α-cyclodextrin, dextran $\documentclass[12pt]{minimal}
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Visual Inspection of the Products After Suspension in the Carrier Liquid {#Sec5}
------------------------------------------------------------------------

Screening of the rough ability of the products to release gas microbubbles was performed using conventional light microscopy.

Area Under the Curve of Acoustic Attenuation and Bubble Half-Time {#Sec6}
-----------------------------------------------------------------

A carrier liquid for determining the acoustic attenuation of the products consisted of 10 mL of propylene glycol mixed with 90 mL of 5% dextrose in water. Each product (1.0 g) was dispersed in the carrier liquid (3.0 mL) and gently handshaken for 15 s. The resulting mixture was added to 5% human serum albumin in phosphate buffer (52 mL). The mixture was placed in a measurement cell with a 5 MHz broadband transducer mounted on one side wall, and an ultrasound-reflecting plate on the opposite side of the cell. A pulse-reflection technique measuring the acoustic transmission through the product dispersions was used to calculate the acoustic attenuation taken as the inverse value of the measured acoustic transmission. The acoustic attenuation (dB/cm) was plotted as a function of time for 390 s. Temperature in the measurement cell was 37 ± 1 °C with constant circulation of the liquid. The results were normalized with regards to measurements of a reference consisting of 55 mL of 5% human serum albumin buffer solution. The calculated integral of the area A under the curve of acoustic attenuation vs. time (390 s), was denoted *A*~390~. This parameter expressed the total amount of gas phase in the dispersions up to and including 390 s. Average bubble lifetime was characterized by the half-time (*t*½) of the acoustic attenuation up to 390 s. Both *A*~390~ and *t*½ were necessary to decide if persistence of ultrasound contrast effect in vitro was improved for the various formulations compared with the reference standards (defined below).

Particle Size Distribution {#Sec7}
--------------------------

The particle size distribution of selected products was analyzed using a Coulter Counter LS 100 or a Malvern Mastersizer light-scattering apparatus by suspending 2 g of the product using a vibrating screen before measuring.

Monitoring of Amphiphiles {#Sec19}
-------------------------

The surfactants, phospholipids and fatty acids milled with the carbohydrates were monitored by analyzing the product (1.0 g) in carrier liquid (3 mL) using thin layer chromatography (TLC) and detecting spots using Nile blue fluorescence and copper complexation as described in the literature \[[@CR11]\].

log *P* Values {#Sec9}
--------------

The concept of hydrophilic-lipophilic balance (HLB) is based on calculations of the ratio of hydrophilic and lipophilic groups in the molecules \[[@CR12]\]. However, HLB values approach zero for many of the compounds used in the present study with low water solubility. Therefore calculated log *P* was found to be a more useful parameter characterizing the amphiphiles used herein. The log *P* values of the amphiphilic compounds were calculated using the chemist drawing and calculation software ChemBioDraw, version 11.0.1, CambridgeSoft Europe Office, 1 Signet Court, Swanns Road, Cambridge CB5 8LA UK.

Data Analysis {#Sec10}
-------------

The parameters defined below were used (abbreviations in parentheses) in a partial least squares analysis (PLS) model with *A*~390~ as a response parameter: % (w/w) amphiphilic material added (% amph); calculated log *P* of the amphiphiles (log *P*); ionic character in sodium salt form (ionicity: 0 or 1); mean particle size in freshly prepared suspensions (psize); % (w/w) α-[d]{.smallcaps}-galactose (%Gal); molecular weight of the amphiphilic additive (LipidMw); degree of unsaturation in the additives as number of double bond equivalents (Unsat: 1--4); number of rings in the chemical structure of the amphiphile (rings); presence of carboxylic acid groups (Carboxyl: 0 or 1). The PLS analysis was performed using the computer program Unscrambler, version 7.01 from CAMO Software AS, Oslo, Norway.

Preparation of Products {#Sec11}
-----------------------

All concentrations are given as % w/w in the procedures. Two literature procedures for preparation of carbohydrate-based gas-releasing ultrasound contrast agents \[[@CR7], [@CR13]\] were modified to establish the three general preparation procedures below. Ball-milling was performed with a Retsch centrifugal ball-mill in a stainless steel ball-mill having a 50 mL grinding cup and 3 × 20 mm balls for 10 min. All products appeared as white powders after milling.

### General Procedure I: Mixtures of Carbohydrates Without Amphiphiles Added, Products **1**--**4** {#Sec12}

Products (**1**) and (**2**) consisted of commercial qualities of α-[d]{.smallcaps}-galactose (**1**) and α-[d]{.smallcaps}-xylose, respectively, that were ball-milled. The α-[d]{.smallcaps}-galactose/Starch Mixtures (**3a-c**) were prepared by mixing α-[d]{.smallcaps}-galactose (3.2, 2.0 and 0.8 g) with starch (0.8, 2.0, and 3.2 g, respectively) followed by ball-milling. The α-[d]{.smallcaps}-galactose/Dextran ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \overline{Mw} $$\end{document}$ 20 kD) mixtures (**4a-b**) were prepared by combining 25.8% solutions of α-[d]{.smallcaps}-galactose in water (29.2 and 19.4 g) with 25.7% solutions of Dextran in water (9.7 and 19.4 g, respectively). The combined solutions were evaporated to dryness while stirring under reduced pressure (10 Torr, 40 °C) and dried in a desiccator overnight. The products were then ball-milled. Experimental data and results for products **1**--**4** are given in Table [1](#Tab1){ref-type="table"}.Table 1*A*~390~ for products **1**--**4** without addition of amphiphilesα-[d]{.smallcaps}-galactose + carbohydrate 2 (C2)Prod.% C2*A*~390~*t* ½ (s)α-[d]{.smallcaps}-galactose (reference 1, **RC1**)**1**0516α-[d]{.smallcaps}-xylose**2**0≈00α-[d]{.smallcaps}-galactose + Starch**3a**2016430**3b**5016135**3c**807038α-[d]{.smallcaps}-galactose + Dextran**4a**252354**4b**501348Milled α-[d]{.smallcaps}-galactose (**1**) is reference product 1 (**RC1**) and corresponds to the commercial product Echovist®. Carbohydrate 1 is milled α-[d]{.smallcaps}-galactose or α-[d]{.smallcaps}-xylose. The added carbohydrate is denoted C2

### General Procedure II: α-[d]{.smallcaps}-galactose-Based Products with Surfactants (**5**--**11**) and Lipophilic Acids (**12**--**19**) {#Sec13}

For each of the products **5**--**19**, the amphiphilic additives were each dissolved in 96% ethanol or water at 50--78 °C. The resulting solutions were filtered and then added to **1** (24.2 g) under stirring. The resulting mixtures were evaporated to dryness under reduced pressure (10 Torr, 40 °C) and the resulting solid products were dried in a desiccator overnight. The residues were ball-milled to give the final products. Experimental data and results for products **5**--**19** are given in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Table 2*A*~390~ for products **5**--**11** comprising α-[d]{.smallcaps}-galactose, milled with amphiphilic compounds lacking a carboxylic acid functionalityAmphiphile A with trivial name (formula, Mw, log *P*) milled with α-[d]{.smallcaps}-galactoseProd.% *AA*~390~*t*½ (s)DPPC (C~40~H~81~NO~8~P, 736.1, 9.8)**5a**0.136653**5b**1.03,712\>500Na-LS (C~12~H~25~NaO~4~S, 266.4 (anion), 1.8)**6a**0.12223**6b**1.06766SMO (C~24~H~46~O~7,~ 446.6, 5.0)**7a**0.1≈00**7b**1.03426STO (C~60~H~110~O~9,~ 975.5, 21.2)**8a**0.1634**8b**1.02872HTBCP (Average Mw 8,400, log *P* n.a.)**9a**0.15821**9b**1.07423Na-Docusate (C~20~H~37~NaO~7~S, 422.6 (anion), 6.1)**10a**0.15523**10b**1.030DOPE (C~44~H~86~NO~8~P, 744.1, 13.6)**11a**0.1343\>500**11b**1.055272For each product, abbreviation or trivial name of the amphiphile (*A*) is followed by formula, molecular weights and calculated log *P* in parentheses. In the last three columns, amounts of *A*, *A*~390~ values and half-times are given. The chemical names of the amphiphiles are given under Materials and MethodsTable 3*A*~390~ values of products **12**--**19** comprising α-[d]{.smallcaps}-galactose, milled with amphiphilic compounds possessing a carboxylic acid functionalityCarboxylic acid C, trivial name (formula, Mw, log *P*) milled with α-[d]{.smallcaps}-galactoseProd.% C*A*~390~*t*½ (s)Capric acid (C~10~H~22~O~2~, 172.3, 4.0)**12a**0.1≈00**12b**1.0≈00Palmitic acid (C~16~H~34~O~2~, 256.4, 7.0) reference 2 (**RC2**) = **13a** (0.1% palmitic acid)**13a**0.135731**13b**0.287135**13c**1.01,061107Hexadecane-dioic acid (C~16~H~34~O~4~, 286.4, 5.1)**14**1.047440Linolenic Acid (C~18~H~30~O~2~, 278.4, 7.3)**15**1.040179Behenic acid (C~22~H~44~O~2~, 340.6, 9.9)**16a**0.12,745\>500**16b**1.04,653\>50010,12-tricosa-diynoic acid (C~23~H~38~O~2~, 346.6, 9.9)**17**0.288451Melissic acid (C~30~H~60~ O~2~, 452.8, 13.8)**18a**0.01322150**18b**0.14,095\>500**18c**1.04,564\>5005β-cholanic acid (C~24~H~40~O~2~, 360.6, 7.7)**19a**0.0116247**19b**0.11,962203**19c**1.04,048\>500Milled α-[d]{.smallcaps}-galactose milled with 0.2% palmitic acid (**13b**) is reference product 2 (**RC2**) and corresponds to the commercial product Levovist®. For each product, abbreviation or trivial name of the carboxylic acid C is followed by the formula, molecular weight and calculated log *P* in parentheses. In the last three columns, amounts of *A*, *A*~390~ values and half-times are given. The chemical names of the amphiphiles are given under "Materials and methods"

### General Procedure III: Palmitic Acid Added to a Mixture of α-[d]{.smallcaps}-galactose (**1**) and Starch (**20**) and Carbohydrates Other than α-[d]{.smallcaps}-galactose (**21**--**24**) {#Sec14}

For **20**, α-[d]{.smallcaps}-galactose (**1**, 12.1 g) was heated to 60 °C and mixed with a 14.3% w/w starch solution in water (35.0 g) before addition of the fatty acid solution. For products **21** and **22**, α-[d]{.smallcaps}-galactose (**1)** was replaced by 41.3% w/w solutions (24.2 g) of α-[d]{.smallcaps}-xylose and maltodextrin, respectively. For **23** and **24**, α-[d]{.smallcaps}-galactose (**1)** was replaced by 22.5% w/w solutions (22.2 g) of glycogen and α-cyclodextrin, respectively. The resulting mixtures were evaporated to dryness under reduced pressure (10 Torr, 40 °C). The resulting solid products were dried in a desiccator overnight and the residues were ball-milled to give the products. Experimental data and results for products **20**--**24** are given in Table [4](#Tab4){ref-type="table"}.Table 4A~390~ values for products **20**--**24** different carbohydrates milled with 0.2% palmitic acidCarbohydrate milled with palmitic acidProductA~390~*t*½ (s)α-[d]{.smallcaps}-galactose + Starch**20**142152α-[d]{.smallcaps}-Xylose**21**706245Maltodextrin**22**254225Glycogen**23**358\>500α-Cyclodextrin**24**9447

Results and Discussion {#Sec15}
======================

Results {#Sec16}
-------

The particle size distributions of the solid products **1**--**24** were in the range of 1--20 μm (Coulter Counter, data not given). In example, a typical accumulated particle volume distribution of **18b** showed that 90% was \<4.4 μm and 10% was \<0.5 μm, the mean diameter was 2.2 μm and the median diameter was 2.1 μm. Based on visual microscopy observation, the solid particles tended to release air bubble dispersions in the size range of 1--15 μm, with some larger bubbles.

For product comparison, two reference compounds were needed: according to the literature and product descriptions \[[@CR7], [@CR13], [@CR14]\], milled α-[d]{.smallcaps}-galactose (**1**) corresponds to the commercial product Echovist® and was chosen as reference product 1 (denoted **RC1**). According to the literature \[[@CR8]\] and public information, the product consisting of α-[d]{.smallcaps}-galactose milled with 0.1% palmitic acid (**13a**) corresponds to the commercial product Levovist®, and was chosen as reference product 2 (denoted **RC2**). The results of the acoustic characterization expressed as *A*~390~ are given in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The results of the measurement of *A*~390~ after mixing with the carrier liquid are given in Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}.Fig. 1Acoustic attenuation (dB/cm) vs. time (390 s) of carbohydrate mixtures without amphiphiles added, compared with the reference standard 1 (**RC1**), milled α-[d]{.smallcaps}-galactose (**1**). When no amphiphiles are present, mixing of α-[d]{.smallcaps}-galactose with polymeric carbohydrates like starch or Dextran with $\documentclass[12pt]{minimal}
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                \begin{document}$$ \overline{Mw} $$\end{document}$ 20 kD only slightly increases A~390~ compared with **RC1**Fig. 2Acoustic attenuation (dB/cm) vs. time (390 s) of different carbohydrates with 0.2% palmitic acid compared with the reference standard 2 (**RC2**), milled α-[d]{.smallcaps}-galactose with 0.2% palmitic acid (**13b**). Adding palmitic acid to different carbohydrates shows that *A*~390~ of **RC2** is superior for the first 100 s compared with the products containing maltodextrin, glycogen and α-cyclodextrin with the same amount of palmitic acidFig. 3Acoustic attenuation (dB/cm) vs. time (390 s) of α-[d]{.smallcaps}-galactose with 1% of different amphiphiles, surfactants and linolenic acid compared with α-[d]{.smallcaps}-galactose containing 1% palmitic acid. The intensity and duration of the acoustic attenuation of all products containing 1% amphiphiles with various log *P* values, but lacking carboxylic acid functionality, is significantly lower than for **RC2**Fig. 4Acoustic attenuation (dB/cm) vs. time (390 s) of α-[d]{.smallcaps}-galactose with 1% of different amphiphiles, higher fatty acids and DPPCFig. 5Acoustic attenuation (dB/cm) vs. time (390 s) of α-[d]{.smallcaps}-galactose with 0.2% of different amphiphiles. When α-[d]{.smallcaps}-galactose is milled with 0.1% of β-cholanic acid (**19b**), behenic acid (**16a**), and melissic acid (**18b**), a significant increase in *A*~390~ compared with **RC2** is observed

Figures [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"} show the statistical analysis of the results, using *A*~390~ as a response parameter. A high log *P*, the presence of α-[d]{.smallcaps}-galactose and that of a carboxylate group in the amphiphilic molecule correlates positively with *A*~390~. In addition, the PLS analysis reveals some interaction effects between parameters. There is a strong interaction between log *P* and the presence of a carboxylate group; an interaction between log *P* and the presence of α-[d]{.smallcaps}-galactose is also evident from the analysis.Fig. 6Results of the PLS analysis including interaction effects (regression coefficients) between parameters derived from principal components 3, 4 and 5 with *A*~390~ as response parameterFig. 7Correlation plot of the observed vs. predicted in vitro contrast effect expressed as *A*~390~ values using the present PLS model

Discussion {#Sec17}
----------

As shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, the use of other carbohydrates than α-[d]{.smallcaps}-galactose does not improve performance (*A*~390~ and *t*½) as compared with the α-[d]{.smallcaps}-galactose-based reference products **RC1** and **RC2**. The observed significant increase in both *A*~390~ and *t*½ when α-[d]{.smallcaps}-galactose is mixed with 0.1% of β-cholanic acid (**19b**), behenic acid (**16a**), and melissic acid (**18b**) compared with **RC2** (Fig. [5](#Fig5){ref-type="fig"}), correlates well with the log *P* values for the acids. The products **16a** and **18b** show half-time *t*½ \> 500 s compared with *t*½ = 31 s for **RC2** (Table [3](#Tab3){ref-type="table"}). For instance, log *P* for 5β-cholanic, behenic and melissic acids are calculated to be 7.7, 9.9 and 13.8, respectively. The *A*~390~ values for the corresponding products **19b**, **16a** and **18b** are 1,962, 2,745 and 4,095, respectively. When the amount of these fatty acids is increased to 1% (products **16b**, **18c** and **19c**, Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) the correlation of *A*~390~ and *t*½ with log *P* is even more pronounced.

An interesting comparison is the results for the products **13c**, **14** and **15**, with 1% (w/w) palmitic acid, hexadecanedioic acid and linolenic acid, respectively (Table [3](#Tab3){ref-type="table"}). Both *A*~390~ and *t*½ are more than 100% higher for **13c** compared with **14**. The dicarboxylic acid **14** will need to bend its lipophilic chain at the gas--water interface, reducing the lipophilic interaction. For linolenic acid (**15**), a highly unsaturated carboxylic acid with a log *P* comparable to palmitic acid, *A*~390~ is at the level of **14** and with a half life of only 79 compared with 107 for **13c** (Table [3](#Tab3){ref-type="table"} and Fig [3](#Fig3){ref-type="fig"}). This may be due du the high number of *cis* double bonds in linolenic acid, giving a non-linear conformation of the lipophilic chain, reducing the hydrophobic interactions between the hydrocarbon chains \[[@CR15]\].

The PLS analysis illustrated by the regression coefficient plot (Fig. [6](#Fig6){ref-type="fig"}) provides further support for the trends observed in the *A*~390~ plots. An absolute high and stable regression coefficient for many principal components indicates a robust effect of the actual descriptor (Fig. [6](#Fig6){ref-type="fig"}). The strongest positive correlation is shown between amphiphiles possessing a carboxylic acid functionality and high log *P* added to α-[d]{.smallcaps}-galactose. This points at fatty acids with a number of carbon atoms \>20, in good compliance with the experimental data. These data are further strengthened by the experimental results for amphiphiles with high log *P* but lacking the carboxyl functionality; all have low *A*~390~ (e.g. the phospholipid-based product **11**). *M*~w~ alone has negligible effect on *A*~390~ as shown by its regression coefficient (Fig. [6](#Fig6){ref-type="fig"}). The good correlation between predicted and observed *A*~390~ values (Fig. [7](#Fig7){ref-type="fig"}) shows that a suitable model explaining the main effects on *A*~390~ has been established. The reliability of the PLS estimated trends was also tested by regressing various logarithmic transformations of the response having a more uniform variation than the original *A*~390~, and unimportant regression coefficients were successively removed. This process gave similar regression coefficients patterns as shown in Fig. [6](#Fig6){ref-type="fig"} regarding the most important parameters affecting *A*~390~ as well as *t*½.

Ultrasonic waves are heavily attenuated at gas--water interfaces \[[@CR1]\]. It has earlier been reported \[[@CR16]\] that a linear correlation between ultrasonic attenuation and interfacial area in a gas--liquid bubble column could be used to estimate the total interfacial area in the system. The same acoustic phenomenon was used in the present study to establish a method to monitor the amount and lifetime of bubble populations generated by milled carbohydrates.

The amphiphiles in the present study with the highest log *P* are practically insoluble in water \[[@CR17]\]. Thus, when the ethanolic solutions of the amphiphiles are added to the aqueous carbohydrate solutions (products **5**--**19**), colloidal suspensions may form. It was shown in a study of fatty acid particle formation in water containing a surfactant \[[@CR18]\] that the particle size of such suspensions depended on the chain length of the fatty acid. Gas bubbles have an affinity for lipophilic particulate surfaces providing stabilization of the gas phase \[[@CR19]--[@CR22]\], providing one possible mechanism for the observed bubble stabilizing effect during the dissolution of the carbohydrate-amphiphile admixtures. However, a more plausible mechanism is the formation of fatty acid Langmuir films at the gas--water interface, systems extensively described in the literature \[[@CR17], [@CR23]--[@CR26]\]. If the amphiphilic compounds are spread on the gas--water interface, reduction of surface tension would result, as shown by isotherm studies in the cited literature. Reduced surface tension would increase bubble stability, explaining the observations in the present study. It is also well known from reports of investigation of aerosol systems that fatty acids with high log *P* tend to be organized at the gas--liquid as Langmuir films \[[@CR17]\]. In that study, it was shown that chain length and the carboxylic acid functionality were important for the interfacial lifetime of the Langmuir films. One question arising is how the fatty acids with the highest log *P* and very limited solubility in water could achieve a dissolved state to form layers at the gas--water interface in the carbohydrate formulations. The ultrasonic influence in the present experiments may aid the dissolution process, as described in literature for systems comprising substances with low water-solubility \[[@CR27]\].

Conclusion {#Sec18}
==========

In conclusion, the response parameters *A*~390~, expressing the amount of gas-phase present during 390 s, and the bubble half-time *t*½ was shown to be useful main parameters in a screening method for increased persistence of the ultrasound contrast effect in vitro. Using these parameters, it was shown that the persistence and amount of released gas bubbles in formulations used in the commercial carbohydrate-based, gas-releasing available and improved ultrasound contrast agents (Echovist® and Levovist® respectively) could be improved more than 10 times using fatty acids with a higher log *P* relative to palmitic acid. Saturated fatty acids with chain length higher than 20 carbon atoms are commercially available, are found in many nutritional products and should find convenient use in pharmaceutical products. Specifically, the increases in *A*~390~ and *t*½ shown for product **19b-c**, and especially products **16a-b** and **18b-c** containing 5β-cholanic, behenic and melissic acid, respectively, are results that encourage further research and in vivo studies. Studies are ongoing to investigate the in vivo properties of the most promising test substances.
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